5
Saamya Biotech
532905 BSE
Saamya Biotech
Healthcare BSE: 532905 Pharmaceuticals & Biotechnology
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Weaknesses
3- Company has low interest coverage ratio.
- Company has a low return on equity of -1.27% over last 3 years.
- Company has high debtors of 1,211 days.
Growth Rate
Revenue Growth
-50% lower than
3Y
Net Income Growth
25% higher than
3Y
Quarterly Results
| Particulars | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 0.03 | 0.09 | 0.03 | 31.61 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0 | 0.01 | 0.01 |
| Operating Profit | -0.03 | -0.09 | -0.03 | -31.61 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | 0 | -0.01 | -0.01 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0.22 | 0.23 | 0.23 | 8.69 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | -0.25 | -0.32 | -0.26 | -40.3 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | 0 | -0.01 | -0.01 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — | 0% | 0% |
| Net Profit | -0.26 | -0.31 | -0.25 | -40.3 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | 0 | -0.01 | -0.01 |
| EPS in Rs | -0.1 | -0.12 | -0.1 | -16.2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Profit & Loss
| Particulars | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 2.35 | 16.28 | 23.29 | 2.98 | 14.03 | 30.21 | 15.12 | 0 |
| Expenses | 0 | 0 | 0 | 0 | 2.32 | 15.85 | 22.71 | 3.24 | 13.69 | 29.98 | 15.25 | 0.03 |
| Operating Profit | 0 | 0 | 0 | 0 | 0.03 | 0.43 | 0.58 | -0.26 | 0.34 | 0.23 | -0.13 | -0.03 |
| OPM % | — | — | — | — | 1.28% | 2.64% | 2.49% | -8.72% | 2.42% | 0.76% | -0.86% | — |
| Other Income | 0 | 0 | 0 | 0 | 0 | -0.12 | 0.65 | -0.04 | -0.05 | 0.03 | 0.11 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0.04 | 0.81 | 0.03 | 0.02 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0.07 | 0.07 | 0.07 | 0.12 | 1 | 0.92 | 0 |
| PBT | 0 | 0 | 0 | 0 | 0.03 | 0.2 | 0.35 | -0.4 | 0.15 | -0.74 | -0.94 | -0.03 |
| Tax % | — | — | — | — | 33.33% | 55% | 20% | -2.5% | 40% | -6.76% | -53.19% | — |
| Net Profit | 0 | 0 | 0 | 0 | 0.02 | 0.09 | 0.28 | -0.4 | 0.1 | -0.68 | -0.44 | -0.03 |
| EPS in Rs | — | — | 0 | 0 | 0.01 | 0.04 | 0.11 | -0.16 | 0.04 | -0.27 | -0.18 | 0 |
| Div. Payout % | — | — | — | — | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8.08 | 8.08 | 23.09 | 23.09 | 23.09 | 23.09 | 24.88 | 24.88 | 24.88 | 24.88 | 24.88 |
| Reserves | 0 | 0.91 | 1.5 | 1.41 | 7.2 | 8.82 | 8.7 | 8.78 | 4.49 | 3.81 | 3.37 |
| Borrowings | 0 | 0.57 | 1 | 0.12 | 0.16 | 0.22 | 0.38 | 0.35 | 4.43 | 3.63 | 3.24 |
| Other Liabilities | 0.33 | 0.03 | 0.28 | 0.16 | 2.88 | 7.7 | 16.73 | 19.11 | 10.77 | 40.62 | 47.84 |
| Total Liabilities | 8.41 | 9.59 | 25.87 | 24.78 | 33.33 | 39.83 | 50.69 | 53.12 | 44.57 | 72.94 | 79.33 |
| Fixed Assets | 0.01 | 0.35 | 0.61 | 0.7 | 1.64 | 1.37 | 1.52 | 1.38 | 11.8 | 10.66 | 9.54 |
| CWIP | 0.57 | 0 | 0 | 0 | 27.81 | 28.75 | 29.02 | 29.34 | 18.25 | 18.25 | 18.25 |
| Investments | 0 | 0 | 8.23 | 0.01 | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 7.83 | 9.24 | 17.03 | 24.07 | 3.87 | 9.71 | 20.15 | 22.4 | 14.52 | 44.03 | 51.54 |
| Total Assets | 8.41 | 9.59 | 25.87 | 24.78 | 33.33 | 39.83 | 50.69 | 53.12 | 44.57 | 72.94 | 79.33 |
Cash Flow
| Particulars | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | -7.45 | -1.03 | -2.22 | -3.85 | 0.39 | -0.74 | -1.01 | -0.19 | -0.22 | 0.62 | 0.08 |
| Investing | -0.58 | -0.44 | -13.65 | 4.7 | -6.18 | -0.85 | -0.51 | -0.29 | 0.5 | 0.17 | 0.31 |
| Financing | 8.03 | 1.47 | 16.04 | -0.98 | 5.81 | 1.56 | 1.52 | 0.45 | -0.27 | -0.8 | -0.39 |
| Net Cash Flow | 0 | 0 | 0.17 | -0.13 | 0.02 | -0.03 | 0 | -0.03 | 0.01 | 0 | 0 |
| Free Cash Flow | -8.03 | -1.37 | -2.49 | -3.94 | -2.36 | -1.6 | -1.52 | -0.48 | 0.28 | 0.79 | 0.39 |
| CFO/OP | — | — | — | — | 1,300 | -172 | -174 | 73 | -65 | 270 | -62 |
Ratios
| Particulars | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | — | — | — | — | 365 | 183 | 288 | 2,573 | 342 | 522 | 1,211 |
| Inventory Days | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash Conversion Cycle | — | — | — | — | 365 | 183 | 288 | 2,573 | 342 | 522 | 1,211 |
| Working Capital Days | — | — | — | — | 138 | 39.91 | 49.37 | 375 | 93.4 | 38.78 | 72.42 |
| ROCE % | — | 0% | 0% | 0% | 0.11% | 1.15% | 3.54% | -0.97% | 0.65% | -2.33% | -3.29% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Saamya Biotech insights
53 extracted metrics + investor summaries across FY06–FY16.
Documents
1
General Updates
10 March 2026 - Pre-clearance approved (Feb 21, 2026) for promoter-group to sell up to holdings (e.g., Tarun 129,800 shares). 10 March 2026 - Pre-clearance approved (Feb 21, 2026) for promoter-group to sell up to holdings (e.g., Tarun 129,800 shares).
2
General Updates
3 March 2026 - Pre-clearance approved Mar 3, 2026 for promoter sales up to 55,000;42,900;19,500 shares (market INR139). 3 March 2026 - Pre-clearance approved Mar 3, 2026 for promoter sales up to 55,000;42,900;19,500 shares (market INR139).
3
General Updates
23 February 2026 - Promoter Maheshbhai Patel pre-cleared to sell up to 10,000 shares; application dated Feb 23, 2026. 23 February 2026 - Promoter Maheshbhai Patel pre-cleared to sell up to 10,000 shares; application dated Feb 23, 2026.
4
General Updates
21 February 2026 - Pre-clearance approved 21 Feb 2026 for promoter group to sell 357,150 shares (multiple promoters). 21 February 2026 - Pre-clearance approved 21 Feb 2026 for promoter group to sell 357,150 shares (multiple promoters).
5
General Updates
19 February 2026 - Promoter Maheshbhai Patel pre-cleared to sell 10,000 shares; closing price Rs138; approved Feb 19, 2026. 19 February 2026 - Promoter Maheshbhai Patel pre-cleared to sell 10,000 shares; closing price Rs138; approved Feb 19, 2026.
Frequently Asked Questions about Saamya Biotech
What does Saamya Biotech (India) Ltd do?
Saamya Biotech (India) Limited,incorporated in India, listed on the Bombay Stock Exchange Limited, the company is engaged in drug intermediates.
Where is Saamya Biotech (India) Ltd (532905) listed?
Saamya Biotech (India) Ltd trades under code 532905 on the BSE.
Which sector does Saamya Biotech (India) Ltd belong to?
Saamya Biotech (India) Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
Company Information
Saamya Biotech (India) Limited,incorporated in India, listed on the Bombay Stock Exchange Limited, the company is engaged in drug intermediates.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/532905.md for Saamya Biotech (India) Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.